|
|
Volumn 21, Issue 5, 2013, Pages 1312-1323
|
|
N2-Trimethylacetyl substituted and unsubstituted-N 4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d] pyrimidine-2,4-diamines: Design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetastatic and antitumor agents
|
|
Author keywords
Antiangiogenic; Antimetastatic; In vivo; Sonogashira coupling
|
|
Indexed keywords
2,2 DIMETHYL N [4 OXO 6 (PYRIDIN 2 YLETHYNYL) 4,7 DIHYDRO 3H PYRROLO[2,3 D]PYRIMIDIN 2 YL]PROPANAMIDE;
4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE;
4 ANILINOPIPERIDINE DERIVATIVE;
6,7 DIMETHYL 2 PHENYLQUINOXALINE;
AMINO ACID DERIVATIVE;
ANGIOGENESIS INHIBITOR;
ANTIMETASTATIC AGENT;
ANTINEOPLASTIC AGENT;
ERLOTINIB;
GEFITINIB;
IMATINIB;
LAPATINIB;
METHOTREXATE;
N [4 [(3 BROMO 4 FLUOROPHENYL)AMINO] 6 (2 PYRIDIN 2 YL ETHYL) 7H PYRROLO[2,3 D]PYRIMIDIN 2 YL] 2,2 DIMETHYLPROPANAMIDE;
N [4 [(3 BROMOPHENYL)AMINO] 6 (2 PYRIDIN 2 YL ETHYL) 7H PYRROLO[2,3 D]PYRIMIDIN 2 YL] 2,2 DIMETHYLPROPANAMIDE;
N [4 [(3 CHLORO 4 FLUOROPHENYL)AMINO] 6 (2 PYRIDIN 2 YL ETHYL) 7H PYRROLO[2,3 D]PYRIMIDIN 2 YL] 2,2 DIMETHYLPROPANAMIDE;
N [4 [(3 ETHYNYLPHENYL)AMINO] 6 (2 PYRIDIN 2 YL ETHYL) 7H PYRROLO[2,3 D]PYRIMIDIN 2 YL] 2,2 DIMETHYLPROPANAMIDE;
N [4 [(3 TRIFLUOROMETHYL 4 FLUOROPHENYL)AMINO] 6 (2 PYRIDIN 2 YL ETHYL) 7H PYRROLO[2,3 D]PYRIMIDIN 2 YL] 2,2 DIMETHYLPROPANAMIDE;
N [4 [(3 TRIFLUOROMETHYLPHENYL)AMINO] 6 (2 PYRIDIN 2 YL ETHYL) 7H PYRROLO[2,3 D]PYRIMIDIN 2 YL] 2,2 DIMETHYLPROPANAMIDE;
N4 (3 BROMO 4 FLUOROPHENYL) 6 (2 PYRIDIN 2 YL ETHYL) 7H PYRROLO[2,3 D]PYRIMIDINE 2,4 DIAMINE;
N4 (3 BROMOPHENYL) 6 (2 PYRIDIN 2 YL ETHYL) 7H PYRROLO[2,3 D]PYRIMIDINE 2,4 DIAMINE;
N4 (3 CHLORO 4 FLUOROPHENYL) 6 (2 PYRIDIN 2 YL ETHYL) 7H PYRROLO[2,3 D]PYRIMIDINE 2,4 DIAMINE;
N4 (3 ETHYLPHENYL) 6 (2 PYRIDIN 2 YL ETHYL) 7H PYRROLO[2,3 D]PYRIMIDINE 2,4 DIAMINE;
N4 (3 TRIFLUOROMETHL 4 FLUOROPHENYL) 6 (2 PYRIDIN 2 YL ETHYL) 7H PYRROLO[2,3 D]PYRIMIDINE 2,4 DIAMINE;
N4 (3 TRIFLUOROMETHYLPHENYL) 6 (2 PYRIDIN 2 YL ETHYL) 7H PYRROLO[2,3 D]PYRIMIDINE 2,4 DIAMINE;
PROTEIN TYROSINE KINASE INHIBITOR;
SEMAXANIB;
SORAFENIB;
SUNITINIB;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
PROTEIN KINASE INHIBITOR;
PROTEIN TYROSINE KINASE;
PYRIMIDINE DERIVATIVE;
PYRROLE DERIVATIVE;
PYRROLO(2,3 D)PYRIMIDINE;
PYRROLO(2,3-D)PYRIMIDINE;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANIMAL TISSUE;
ANTIANGIOGENIC ACTIVITY;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
CANCER INHIBITION;
CONTROLLED STUDY;
DRUG BINDING SITE;
DRUG DESIGN;
DRUG POTENCY;
DRUG SCREENING;
DRUG SPECIFICITY;
DRUG SYNTHESIS;
HUMAN;
HUMAN CELL;
IN VIVO STUDY;
LIQUID CHROMATOGRAPHY;
LUNG METASTASIS;
MICROWAVE RADIATION;
MOUSE;
NONHUMAN;
SONOGASHIRA REACTION;
STRUCTURE ACTIVITY RELATION;
STRUCTURE ANALYSIS;
TUMOR CELL CULTURE;
TUMOR VASCULARIZATION;
TUMOR XENOGRAFT;
WHOLE CELL;
ANIMAL;
CELL SURVIVAL;
CHEMISTRY;
DISEASE MODEL;
DRUG ANTAGONISM;
DRUG EFFECT;
EXPERIMENTAL MELANOMA;
METABOLISM;
NUDE MOUSE;
TUMOR CELL LINE;
ANGIOGENESIS INHIBITORS;
ANIMALS;
ANTINEOPLASTIC AGENTS;
CELL LINE, TUMOR;
CELL SURVIVAL;
DISEASE MODELS, ANIMAL;
DRUG DESIGN;
HUMANS;
MELANOMA, EXPERIMENTAL;
MICE;
MICE, NUDE;
MICROWAVES;
PROTEIN KINASE INHIBITORS;
PYRIMIDINES;
PYRROLES;
RECEPTOR PROTEIN-TYROSINE KINASES;
STRUCTURE-ACTIVITY RELATIONSHIP;
|
|
EID: 84873730391
PISSN: 09680896
EISSN: 14643391
Source Type: Journal
DOI: 10.1016/j.bmc.2012.12.045 Document Type: Article |
|
Times cited : (16)
|
|
References (44)
|
